JAK Inhibition Immunotherapy for APS-1
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2403419 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Maureen A Su. Beteiligte Einrichtung: From the Department of Microbiology, Immunology, and Molecular Genetics and the Department of Pediatrics, David Geffen School of Medicine at Universi…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Polyendocrinopathies, Autoimmune. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
This editorial describes the science behind a study of the mechanism and treatment of autoimmune polyendocrine syndrome type 1 (also known as APECED), which is caused by damaging variants in the gene AIRE .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Microbiology, Immunology, and Molecular Genetics and the Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles.
ORCID-Profile: Maureen A Su
Zitieren
APA
Su, M. A. (2024). JAK Inhibition Immunotherapy for APS-1. New England Journal of Medicine. https://doi.org/10.1056/nejme2403419
Vancouver
Su MA. JAK Inhibition Immunotherapy for APS-1. New England Journal of Medicine. 2024. doi:10.1056/nejme2403419
BibTeX
@article{Su2024,
author = {Su, Maureen A},
title = {JAK Inhibition Immunotherapy for APS-1},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2403419}
}
EUVIMED